The Center for Commercialization of Cancer Immunotherapy (C3i) and the Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal (CIUSSS-EMTL) are proud to announce the participation of Gilead Sciences Canada, Inc. in supporting the development of a Lymphoma Registry. This registry, launched in September 2017 under the leadership of Dr. Isabelle Fleury, hematologist and medical oncologist at HMR-CIUSSS, is the basis to conduct Real World Evidence (RWE) studies in lymphoproliferative disorders in order to capture specific clinical patterns and provide unique insight in the outcomes of patients treated outside of clinical trials.
“We are extremely pleased with the participation of Gilead Sciences Canada in this project” said Dr Isabelle Fleury and Francois Bettez, Chief Executive Officer of C3i. “This is a clear commitment to support this important initiative that will help improving the care of the patients. We thank Dr. Fleury for her exceptional involvement in this registry, the CIUSSS-EMTL as well as our partners for participating in the development of the Lymphoma registry” said Francois Bettez
“Engaging with healthcare practitioners and organizations is critical to Gilead’s efforts in advancing the treatment of life-threatening diseases in areas of unmet medical need.” said Kennet Brysting, Vice President and General Manager at Gilead Sciences Canada, Inc. “This registry is an innovative and necessary step towards improving the care and outcomes of people living with lymphomas and will surely provide valuable insights into this life-threatening illness. We are pleased to support HMR in this initiative and are privileged to have been considered to support their great work.”
The Centre for Commercialization of Cancer Immunotherapy (C3i) is a unique entity created in early 2016 with the ultimate goal to accelerate access to innovative cancer immunotherapies for Canadians. Our vision is to be Canada’s catalyst for cancer immunotherapy business development. C3i will be the only Canadian immunotherapy development organisation that will lead to the clinical implementation and to the commercialization of these new therapeutic methods. To this end, we propose a novel business model combining direct patient clinical diagnostics using new genomic technologies, good manufacturing practices (GMP) standards and rapid access to clinical trials and regulatory support. https://centrec3i.com
Le Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal (CIUSSS-EMTL) includes the Maisonneuve-Rosemont Hospital, Santa Cabrini Hospital, and the Marie-Curie Polish CHSLD. Sklodowska and the Montreal Mental Health University Institute, as well as Saint-Léonard and Saint-Michel Health and Social Services Centers, Pointe-de-l’Île and Lucille-Teasdale. It has nearly 15,000 employees and nearly 1,000 physicians in 43 service points for a population of 500,000 people. It offers a full range of front-line health and social services, general, specialty, subspecialized and mental health care. It also offers long-term care in accommodation. Affiliated with the University of Montreal, the CIUSSS-EMTL combines teaching, evaluation and research missions with the training of doctors and health professionals. Its two major research centers stand out nationally and internationally in areas of expertise such as mental health, immuno-oncology, vision health, nephrology and cell therapy. www.ciusss-estmtl.gouv.qc.ca.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences Canada, Inc. is the Canadian affiliate of Gilead Sciences, Inc., and was established in Mississauga, Ontario in 2006. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.